Posted inBiotechnology
Early Career Funding Boosts UK Research Success Equally
In the relentless pursuit of scientific excellence, funding often serves as the lifeblood that nurtures early career researchers, propelling them…
Posted inBiotechnology
Serum FAM132A Links Obesity to Endothelial Dysfunction
In a groundbreaking investigation into the early cardiovascular risks faced by children with obesity, researchers have identified a crucial biomarker…
Posted inBiotechnology
Accelerating NiCoCr Alloy Discovery via Active Learning
In the ever-evolving realm of materials science, the quest for novel alloys with enhanced properties has long been a cornerstone…
Posted inBiotechnology
Inflammation Resolution Failure in Intracerebral Hemorrhage
Intracerebral haemorrhage (ICH) remains one of the most devastating neurologic conditions, marked by high mortality and profound long-term disability. Despite…
Posted inBiotechnology
Health and Lifestyle of Older Adults in Dhankuta
In the remote and scenic Hilly Municipality of Dhankuta, Nepal, a groundbreaking new study sheds light on the pressing health…
Posted inBiotechnology
Building Trust with Uncertainty-Aware AI in Lung Cancer
In the relentless pursuit of precision medicine, artificial intelligence (AI) has emerged as a beacon of innovation, particularly in the…
Posted inBiotechnology
Revolutionizing Alkaline Water Electrolysis for Industry
For over a century, alkaline water electrolysis (AWE) has formed the backbone of industrial hydrogen production, dominating the landscape of…
Posted inBiotechnology
Front-line Chemo-Immunotherapy: New Hope for Penile Cancer
In recent years, the landscape of penile cancer treatment has witnessed remarkable scientific advances, steering the therapeutic strategies from conventional…
Posted inGenetics
Three Subtypes of Severe Pneumonia Might Inform Personalized Therapies
The results of a study headed by researchers at the University of Cambridge suggest that severe pneumonia has three different…
Posted inBiotechnology
Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet
Half a year after toppling Genentech’s eye medicine giant Vabysmo in an early trial, Texas biotech Ollin Biosciences has lassoed…